Gabelli & Co Investment Advisers’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-205,800	Closed	-$4.75M	–	527
2020 Q4	$4.75M	Buy	+205,800	New	+$2.61M	0.74%	32

Gabelli & Co Investment Advisers's PRVL Position: Q1 2021 in Review

Gabelli & Co Investment Advisers sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 205,800 shares — an estimated $4.75M sold.

Gabelli & Co Investment Advisers first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $4.75M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Gabelli & Co Investment Advisers reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Gabelli & Co Investment Advisers sold 205,800 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $4.75M.
Gabelli & Co Investment Advisers first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Gabelli & Co Investment Advisers's Prevail Therapeutics Inc. Common Stock position peaked at $4.75M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2021, filed 14 May 2021.